Gain Therapeutics, Inc. (GANX)
| Market Cap | 78.15M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.16M |
| Shares Out | 42.24M |
| EPS (ttm) | -0.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 449,811 |
| Open | 1.940 |
| Previous Close | 1.950 |
| Day's Range | 1.850 - 1.970 |
| 52-Week Range | 1.410 - 4.340 |
| Beta | 0.11 |
| Analysts | Strong Buy |
| Price Target | 7.50 (+305.41%) |
| Earnings Date | May 13, 2026 |
About GANX
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company’s lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson’s... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for GANX stock is "Strong Buy." The 12-month stock price target is $7.5, which is an increase of 305.41% from the latest price.
News
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...
Gain Therapeutics Transcript: The 38th Annual Roth Conference
A novel approach to Parkinson's targets disease biology by stabilizing GCase, with early clinical data showing safety, biomarker engagement, and stable motor scores. Phase II trials will stratify patients by biomarkers and begin in Q3, with further pipeline candidates in development.
Gain Therapeutics to Present at the 38th Annual ROTH Conference
BETHESDA, Md., March 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals wit...
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
Interim analysis of Phase 1b clinical study of GT-02287, including biomarker and clinical endpoints, will be presented in oral symposium Company remains on track to initiate Phase 2 clinical trial of ...
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
BETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Gain Therapeutics Transcript: Study Update
GT-02287 showed promising biomarker and clinical signals in a phase 1b Parkinson's study, with reductions in CSF glucosylsphingosine correlating to UPDRS improvements. The drug's mechanism targets GCase pathway dysfunction, and further validation in phase II is planned.
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
BETHESDA, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease
BETHESDA, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease
Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint The reduction in GluSph in CSF, a first-ever o...
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
GT-02287 reduces mitochondrial stress and enhances neuronal survival in MPP+ treated rat dopaminergic neurons GT-02287 decreases staining for MIRO1, suggesting improved mitochondrial health in α-synuc...
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical models in vivo and the proposed mechanism of action Completed enrollment of ...
Gain Therapeutics to Present at Neuroscience 2025
BETHESDA, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
BETHESDA, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Gain Therapeutics Transcript: Study Result
A phase I-B study of GT-02287 in Parkinson's disease shows favorable safety and early signs of clinical improvement, with most adverse events mild and a majority of patients entering a nine-month extension. Biomarker and full clinical data are expected by year-end, with a phase II trial planned for next year.
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®
Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participants
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
BETHESDA, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease
Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing schedule
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
Ongoing Phase 1b trial of GT-02287 to be extended by an additional nine months for participants who enrolled in the original three-month study design The independent data monitoring committee (DMC) me...
Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
Reached full enrolment of Phase 1b study evaluating GT-02287 in Parkinson's Disease (PD) with or without GBA1 mutations during 2Q 2025, earlier than anticipated Analysis of functional changes and biom...
Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference
BETHESDA, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
BETHESDA, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Gain Therapeutics Announces Proposed Public Offering
BETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...